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Murraya koenigii Spreng has been traditionally claimed as a remedy for cancer.The current study investigated the anticancer effects
of girinimbine, a carbazole alkaloid isolated from Murraya koenigii Spreng, on A549 lung cancer cells in relation to apoptotic
mechanistic pathway. Girinimbine was isolated from Murraya koenigii Spreng. The antiproliferative activity was assayed using
MTT and the apoptosis detection was done by annexin V and lysosomal stability assays. Multiparameter cytotoxicity assays were
performed to investigate the change in mitochondrial membrane potential and cytochrome c translocation. ROS, caspase, and
human apoptosis proteome profiler assays were done to investigate the apoptotic mechanism of cell death.TheMTT assay revealed
that the girinimbine induces cell death with an IC
50
of 19.01 𝜇M. A significant induction of early phase of apoptosis was shown
by annexin V and lysosomal stability assays. After 24 h treatment with 19.01 𝜇M of girinimbine, decrease in the nuclear area and
increase inmitochondrialmembrane potential and plasmamembrane permeability were readily visible.Moreover the translocation
of cytochrome c alsowas observed. Girinimbinemediates its antiproliferative and apoptotic effects through up- and downregulation
of apoptotic and antiapoptotic proteins. There was a significant involvement of both intrinsic and extrinsic pathways. Moreover,
the upregulation of p53 as well as the cell proliferation repressor proteins, p27 and p21, and the significant role of insulin/IGF-1
signaling were also identified. Moreover the caspases 3 and 8 were found to be significantly activated. Our results taken together
indicated that girinimbine may be a potential agent for anticancer drug development.
1. Introduction
Lung cancer is one of the leading causes of cancer related
deaths worldwide, which has a high incidence of recurrence.
It has been estimated that approximately 1.4 million are
diagnosed every year and more than 1 million people die
annually, 12% of which are new cases [1]. Nonsmall cell lung
cancer (NSCLC) constitutes majority of lung cancers, which
comprises more than 80% of total diagnoses [2]. Although
chemotherapy and radiation therapy are available to treat
NSCLC, they are largely ineffective and highly toxic with
a low survival profile [3]. This toxicity and resistance to
the current chemotherapy made researchers focus on new
drug candidates, targeting apoptosis, a programmed cell
death, as physiological process that provides an effective,
noninflammatory way to remove redundant or damaged
cells from tissues thereby securing tissue homeostasis [4].
A multitude of signals activated by variable triggers, such
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Figure 1: Effects of girinimbine on cell viability in A549 cells. (a)The chemical structures of girinimbine. (b)The cell viability of cells after 24 h
of girinimbine treatment. Each point is the mean ± SD of three independent experiments. (c) IC
50
values of both girinimbine and paclitaxel
(positive control).
as growth factors, cell-cell interactions, changing nutrient
conditions, hypoxic conditions, and cytotoxic damage, affect
the status of the apoptotic machinery [5], and it is an
effective means of treating cancer, including NSCLC [6]. The
literature on drug discovery published to date reveals that the
knowledge of ethnopharmacology and traditional medicine
has contributed a lot to development of novel clinical agents.
“Ayurveda,” an Indian system of medicine, is gaining
greater attention and reputation inmany regions of the world
due to increased acceptance to the scientific evidence base
and the essence of vigorous research. Depending on themode
of action, the Ayurvedic pharmacology system classifies
medicinal plants into different groups. As per Ayurveda,
plants identified as “Rasayanas” have various pharmacolog-
ical properties such as being immunostimulant, anticancer,
tonic, neurostimulant, antiaging, antibacterial, antiviral, and
antirheumatic [7]. The use of “Rasayana” as a body resistance
enhancer has been described in detail in a distinct section of
Ayurveda. Murraya koenigii, an aromatic small tree, belong-
ing to the citrus family, Rutaceae, that grows widely in East
Asia, is one such plant which is reported as tonic and used
in various disease conditions [8]. The traditional medical
literature describes its potential role as a remedy for cancer
[9]. Moreover, other uses such as antioxidant properties
and antidiabetic, antifungal, antibacterial, antidysentery, and
antidiarrhea effects have also been investigated [10].
The main constituents reported from the plants are ster-
ols, aminoacids, glycosides, proteins, and flavonoids. Apart
from these, many carbazole alkaloids also have been iden-
tified. It has been reported that carbazole alkaloids present
in the plant have numerous biological activities such as anti-
tumor, antioxidative, and anti-inflammatory activities [9].
Ramsewak et al. (1999) had reported that carbazole alkaloids
obtained fromM. koenigii show cytotoxic capacity [11]. Even
though many carbazole alkaloids have been isolated and
identified from the different parts ofM. koenigii, girinimbine
was the first [12]. The effect of carbazole alkaloids in cancer
has been studied in detail [13]. Recently, girinimbine and
some structurally similar compounds isolated from the M.
koenigii plant had showed that the anticancer effect of this
compound involves apoptosis and free radical scavenging
[14, 15]. But the involvement of proteins implicated in the
intrinsic and/or extrinsic pathways including other apop-
tosis proteins has not been studied yet. In an effort to
understand the mechanism behind the anticancer traditional
pharmacological claim of this plant and to know the role
of these proteins in cell death, we used A549 cells, which
were shown to undergo apoptosis following exposure to
girinimbine.
2. Materials and Methods
2.1. Isolation ofGirinimbine. Theroot ofMurraya koenigii (L.)
Sprengwas collected fromSik, Kedah,Malaysia, in June 2006.
The experimental work on plant to obtain pure girinimbine
(Figure 1) and its spectroscopic data has been reported pre-
viously [16]. Briefly, the air-dried sample (525 g) was ground
and further extracted with solvents usingmicrowave-assisted
extraction (45∘C, 300W for one hour). This process gave
a hexane extract (22.7 g), chloroform extract (11.7 g), and
methanol extract (40.7 g). Part of the hexane extract (20.7 g)
was subjected to column chromatography fractionation with
a combination solvent system of hexane, ethyl acetate, and
methanol in increasing polarity to give 40 fractions. Fractions
9–14 which were eluted from hexane : ethyl acetate (95 : 5
≥ 92 : 8) were combined and rechromatographed over sil-
ica gel to yield a yellow solid which was then recrystal-
lized with hexane to obtain white crystals of girinimbine
(0.77 g). The melting point of girinimbine was 171–173∘C
[16].The isolated compound (girinimbine) was characterized
by infrared spectroscopy, mass spectrometry, and nuclear
magnetic resonance (1H and 13C NMR). The confirmation
of the compound as well as the purity was again checked
using HPLC and LC-MS. Further information regarding the
mass spectra and purity of girinimbine can be obtained from
the supplementary information provided, available online at
http://dx.doi.org/10.1155/2013/689865.
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2.2. Cell Culture. A549, a human nonsmall cell lung cancer
cell line, was purchased from ATCC (Rockville, MD, USA)
and cultured in RPMI-1640 supplemented with 100 𝜇L/mL
fetal bovine serum, 100U/mL penicillin, and 100mg/mL
streptomycin sulfate. Cells were maintained at 37∘C in a
humidified atmosphere of 5% CO
2
. Cells were treated with
the girinimbine dissolved in DMSO, while the untreated
control cultures received only the vehicle (DMSO < 1%).
2.3. Cell Viability Assay. Cells were seeded in 96-well plates
at a density of 1 × 104 per well and treated with various con-
centrations of girinimbine for 24 h. Cells were then incubated
with a medium containing 5mg/mL 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) for another
4 h. The viable cell number was directly proportional to
formazanproductionwhich thendissolved inDMSOandwas
measured by spectrophotometry at 563 nm in a microplate
reader (Tecan Infinite M 200 PRO, Ma¨nnedorf, Switzerland)
[17].
2.4. Microscope Examination on Cellular Morphology. Apop-
tosis was monitored by annexin V labeling and fluorescence
microscopy [18]. Treated and untreated cells were washed
with PBS and then exposed with annexin V-fluorescein (BD
Pharmingen, USA) for 15mins. After a 488 nm excitation,
green fluorescence was visualized and recorded at 515 nm.
Phase contrast microscopic images from the same prepara-
tions were also obtained for symptoms of apoptosis such as
cell shrinkage, ruffling, and blebbing of cell membrane as well
as fragmentation of cells into small apoptotic bodies using
a fluorescent microscope (Nikon TE 2000U fluorescence
inverted microscope, Tallahassee, Florida).
2.5. Determination of Lysosomal Membrane Stability. Cells
were assessed for lysosomal stability using acridine orange
(AO) uptake assay. Briefly, cells were incubated with 7𝜇M
AO (Sigma, USA) and 12 𝜇M Hoechst 33342 (Invitrogen,
Carlsbad, CA, USA), diluted in culture media for 15mins
at 37∘C, and immediately observed and analyzed using the
ArrayScan HCS system (Cellomics, PA, USA). Acridine
orange is ametachromatic fluorochrome and aweak base that
exhibits red fluorescence when highly concentrated in acidic
lysosomes.
2.6.Measurement of Reactive Oxygen Species Generation. The
production of intracellular reactive oxygen species (ROS)was
measured using 2󸀠,7󸀠-dichlorofluorescein diacetate (DCFH-
DA) [19]. DCFH-DA passively enters the cell where it
reacts with ROS to form the highly fluorescent compound
dichlorofluorescein (DCF). Briefly, 10mM DCFH-DA stock
solution (in methanol) was diluted 500-fold in HBSS without
serum or other additives to yield a 20𝜇M working solution.
After 24 h of exposure to girinimbine, the cells in the 96-well
black plate were washed twice with HBSS and then incubated
in 100 𝜇L working solution of DCFH-DA at 37∘C for 30mins.
Fluorescence was then determined at 485 nm excitation and
520 nm emission using a fluorescence microplate reader
(Tecan Infinite M 200 PRO, Ma¨nnedorf, Switzerland).
2.7. Multiple Cytotoxicity Assay. Cellomics Multiparameter
Cytotoxicity 3 Kit was used as described in detail previously
[20].This kit enables simultaneousmeasurements in the same
cell of six independent parameters that monitor cell health,
including cell loss, nuclear size and morphological changes,
mitochondrial membrane potential changes, cytochrome c
release, and changes in cell permeability. Plates were analyzed
using the ArrayScan HCS system (Cellomics, PA, USA).
2.8. Image Acquisition and Cytometric Analysis. Plates with
stained cells were analyzed using the ArrayScan HCS sys-
tem (Cellomics, PA, USA). This system is a computerized
automated fluorescence imaging microscope that automat-
ically identifies stained cells and reports the intensity and
distribution of fluorescence in individual cells. The Array-
Scan HCS system scans multiple fields in individual wells
to acquire and analyze images of single cells according to
defined algorithms. In each well, 1,000 cells were analyzed.
Automatic focusing was performed in the nuclear channel
to ensure focusing regardless of staining intensities in the
other channels. Images were acquired for each fluorescence
channel, using suitable filters. Images and data regarding
intensity and texture of the fluorescence within each cell, as
well as the average fluorescence of the cell population within
the well, were stored in a Microsoft SQL database for easy
retrieval. Data were captured, extracted, and analyzed with
ArrayScan II Data Acquisition and Data Viewer version 3.0
(Cellomics).
2.9. HumanApoptosis Proteome Profiler Array. To investigate
the pathways by which girinimbine induces apoptosis, we
performed a determination of apoptosis-related proteins
using the Proteome Profiler Array (RayBio Human Apop-
tosis Antibody Array Kit, RayBiotech, USA), according to
manufacturer’s instructions. In short, the cells where treated
with 19 𝜇M girinimbine. 300 𝜇g proteins from each sam-
ple and were incubated with the human apoptosis array
overnight. The apoptosis array data were quantified by scan-
ning the membrane on a Biospectrum AC ChemiHR 40
(UVP, Upland, CA) and analysis of the array image file was
performed using image analysis software according to the
manufacturer’s instruction.
2.10. Measurement of Caspases 8, 9, and 3/7 Activities. Cas-
pases 3/7, 8, and 9 activity wasmeasured using luminescence-
based assay, Caspase-Glo 8 Assay, Caspase-Glo 9 Assay, and
Caspase-Glo 3/7 Assay (Promega). 1 × 104 cells were cultured
in 96-well culture plates in 50 𝜇L of RPMI 1640 supplemented
with 10% FBS and incubated for 24 h. Cells then were treated
with different concentrations of girinimbine and incubated
for 24 h. At the end of incubation, 100 𝜇L of assay reagent was
added to be incubated for 1 h at room temperature. Lumines-
cence wasmeasured using amicroplate reader (Tecan Infinite
M 200 PRO, Ma¨nnedorf, Switzerland).
2.11. Statistical Analysis. From several independent measure-
ments means and standard deviations were calculated. Test-
ing for significant differences between means were carried
4 Evidence-Based Complementary and Alternative Medicine
(a) (b) (c)
(d) (e) (f)
Figure 2: Effects of girinimbine on the morphological changes of A549 cells after 24 h treatment. Apoptosis was monitored by phase contrast
((a) control, (b) treatment 9𝜇M, and (c) treatment 19𝜇M) and fluorescence microscopy ((d) control, (e) treatment 9𝜇M, and (f) treatment
19𝜇M). Arrows indicate the cell shrinkage, ruffling, and blebbing of cell membrane while arrowheads indicate the annexin V binding to
phosphatidylserine. Magnification 20X.
out using the one-way ANOVA and Dunnett’s post-test at
probabilities of error of 5% and 1%.
3. Results
3.1. Antipoliferative Activity. The sigmoidal dose response
curves of girinimbine in the end-point assays are shown in
Figure 1. Cell viability was analyzed using the MTT assay,
which measures the metabolic activity of cell. In the A549
cells treated with girinimbine, metabolic activity decreased
followed by 24 h treatment; meanwhile in the control plate,
cell viability and metabolism were not affected. Figure 1(c)
summarizes the IC
50
values from MTT. Meanwhile, even at
380 𝜇M girinimbine could not exhibit any sign of toxicity in
WRL-68, a normal (data not shown) which was employed in
this study to investigate the specificity of cytotoxicity.
3.2. Apoptotic Mode of Cell Death. Data obtained from
fluorescence detection of A549 cells together with the phase
contrast microscopic images are shown (Figure 2). Apoptosis
was clearly detected by the phosphatidylserine externaliza-
tion on the treated cells. Phase contrast microscopic pictures
showed a clear morphological change of treated cells which
were observed after 24 h of treatment with girinimbine. A549
cells were seen to have shrunk in size and there was ruffling
and blebbing of cell membranes, thus suggesting that the cells
were undergoing apoptosis (Figure 2(c)).
3.3. Girinimbine Initiates Lysosomal Membrane Permeabiliza-
tion. Recent studies have shown that lysosomal membrane
permeabilization (LMP) is an early and perhaps initiating
event in apoptosis triggered by ligation of death recep-
tors, lysosomotropic agents, oxidative stresses, or serum
withdrawal [21, 22]. To evaluate the lysosome acidification
pattern, the cells were analyzed by acridine orange staining,
a known pH indicator. While untreated A549 cells dis-
played strong granular acridine orange staining, cells treated
with girinimbine presented weak lysosome staining pattern
and cytoplasm acidification, indicating lysosomal membrane
permeabilization (Figures 3(a)–3(c)). Girinimbine induced
dose-dependent decrease of fluorescence intensity of lyso-
somal staining, which was well compared with chloroquine,
a known inhibitor of lysosome function, was included as a
positive control (Figure 3(d)).
3.4. ROS Assay. Numerous investigations have documented
that oxidative stress-mediated cellular changes are fre-
quently induced in cells exposed to cytotoxic drugs, UV, or
gamma irradiation [23, 24]. We examined whether girin-
imbine affects the cellular levels of peroxide by measur-
ing the changes in the fluorescence using DCF-DA. As
shown in Figure 4(a), treatment with girinimbine markedly
increased the DCF-DA-derived fluorescence (520 nm). This
girinimbine-mediated increase in fluorescence was markedly
inhibited by pretreatment with antioxidant ascorbic acid.
Then, we next asked whether ROS generation induced by
girinimbine is directly associated with the induction of
apoptosis. Chromatin condensation was measured in the
cells which were pretreated with ascorbic acid, using 12𝜇M
Hoechst 33342. The results shown in Figure 4(b) clearly
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Figure 3: Effects of girinimbine onA549 cells lysosome acidic environment. Cells were incubatedwith different concentrations of girinimbine
for 24 h, stained with acridine orange and analyzed by ArrayScan HCS system. Control group corresponds to untreated cells. Acridine orange
is a metachromatic fluorochrome and a weak base that exhibits red fluorescence when highly concentrated in acidic lysosomes. (a) Normal
lysosome acidic environment (arrow).Notice theweak lysosome staining pattern and cytoplasm acidification (arrowhead) in cells treatedwith
chloroquine (b) and girinimbine (c), indicating lysosomal membrane permeabilization. Magnification 20X. The mean fluorescent intensity
produced by the acridine orange was quantitatively measured (Figure 3(d)).
exhibited that pretreatment with ascorbic acid could not
prevent the apoptosis at various time periods. Moreover, the
data clearly shows the rapid decrease in the nuclear area and
the increase in fragmentation, upon treatment with 19 𝜇M
girinimbine (Figure 4(c)).
3.5. Multiparameter Cytotoxicity Analysis. This assay enables
simultaneousmeasurement of several cell-health parameters:
nuclear morphology, DNA content, cell membrane perme-
ability, and cytochrome c localization and release frommito-
chondria. Typical cytotoxic changes are illustrated in Figures
5 and 6. Girinimbine induced decreases in cell number;
nuclear area intensity and plasma membrane permeability
were significantly higher in the treated cells (𝑃 < 0.01) and
mitochondrial membrane potential reduction was observed
significantly at 19𝜇M (𝑃 < 0.01). The release of cytochrome
c was observed significantly in 9𝜇M and 19𝜇M with 𝑃 <
0.05 and 𝑃 < 0.01, respectively. These effects occurred
more rapidly and followed a dose-response pattern. Cytotoxic
effects were considered to occur only when the rate of change
of fluorescence was distinctly greater than for the negative
controls.
3.6. Effect of Girinimbine on Apoptotic Markers. After girin-
imbine (19𝜇M) exposure, A549 cells were lysed and apoptotic
markers where screened using a protein array. All major
markers which are involved in both intrinsic and extrinsic
pathways were induced on treatment. As shown in Figure 7,
girinimbine treatment significantly increased the expression
of caspase 8, suggesting the activation of the death receptor
pathway. In addition, the major protein involved in the
extrinsic pathway such as Fas and FasL also regulates the
treatment. Moreover the involvement of mitochondria in the
cell death was evident by the regulation of the Bcl-2 family
of proteins such as Bad, Bax, Bcl-2, and Bim. Besides, the
Bcl-2 family member Bid was found to be cleaved as well,
suggesting a potential cross-talk between the death receptor
and the mitochondrial pathway. The treatment also resulted
in a reduction in the level of expression of the inhibitor
of apoptosis XIAP as well as survivin. P53 as well as the
cell proliferation repressor proteins, p27 and p21, and the
heat shock proteins such as antiapoptotic HSP60, HSP70,
and HSP27, which are a result of oxidative stress in the cell,
were also induced. Insulin/IGF-1 signaling related protein
expression has been observed on treatment. Downregulation
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Figure 4: Effects of girinimbine on A549 cells ROS generation. (a) DCF-fluorescence intensity after ascorbic acid and 19 𝜇M of girinimbine
exposure at 4, 8, and 24 h. Rate of apoptosis in terms of fluorescent intensity (b) and average nuclear object size (c) of nucleus of the girinimbine
treatment was pretreatedwith 100mMascorbic acid. Values aremean± SD from three independent experiments. Triplicates of each treatment
group were used in each independent experiment. The statistical significance is expressed as ∗∗𝑃 < 0.01; ∗𝑃 < 0.05. Fluorescent intensity
units directly represent the amount of ROS production.
of antiapoptosis (IGF-I, IGF-II, IGFBP1, IGFBP2) and upreg-
ulation of proapoptosis proteins (IGFBP3, IGFBP4) were
observed.
3.7. Caspase Depended Apoptosis in Girinimbine Treated A549
Cells. The involvement of the caspase cascade in the girin-
imbine mediated cell death was confirmed. The treatment
with 19 𝜇M was significant at 𝑃 < 0.01 for caspase 3/7
and 9 with 8- and 5-fold increase, respectively. Meanwhile
the caspase 8 showed 10-fold increase at the maximum
treatment concentration (19 𝜇M, 𝑃 < 0.01) (Figure 8).
These results are in parallel with the protein array and
indicate that the signaling cascade leading to apoptosis in
girinimbine-treated cells involves both intrinsic and extrinsic
pathways.
4. Discussion
Apoptosis is a normal physiological process that plays a
vital role in numerous normal functions [4]. Furthermore,
it is an active physiological process causing cellular self-
destruction that comprises specific morphological and bio-
chemical changes in the nucleus and cytoplasm [25]. The
involvement of an energy-dependent cascade of molecular
events makes the mechanism of apoptosis very highly com-
plex and sophisticated [26]. Apoptosis is regulated by two
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Hoechst 33342 Cell permeability Cytochrome c
C
on
tro
l 
G
iri
ni
m
bi
ne
 
Mitochondrial 
membrane potential
Figure 5: Representative images of A549 cells treated withmedium alone and 19 𝜇Mof girinimbine and stained with Hoechst for nuclear, cell
permeability dye, mitochondrial membrane potential dye, and cytochrome c. The images from each row are obtained from the same field of
the same treatment sample. A549 produced a marked reduction in mitochondrial membrane potential and marked increases in membrane
permeability and cytochrome c. Magnification 20X.
major pathways: the extrinsic and the intrinsic pathways
[27]. Nevertheless, there is evidence suggesting that both
the pathways are linked and that molecules involved in the
pathways can influence one another [28].
The current study found that girinimbine, a carbazole
alkaloid from the roots of M. koenigii, can inhibit cell
proliferation selectively in a dose dependent manner in
A549 cells. The morphological observation was conducted
to explore whether the cytotoxic effect was related with
the apoptotic process, and it was found that the cell death
induced by girinimbine exhibited a clear morphological
sign of apoptosis, as this is an important property of a
candidate anticancer drug [29]. Followed by 24 h treatment,
cell shrinkage, ruffling, and blebbing of cell membranes were
observed. These morphological features were more evident
while we analysed one of the key features of apoptosis, which
is the change in plasma membrane structure by surface
exposure of phosphatidylserine (PS), while the membrane
integrity remains unchallenged [30]. The incorporation of
annexinV in to the same treated cells showed distinctive form
of binding between the externalized PS and Annexin V, while
cells from test flasks showedmore evidence of apoptosis than
those grown under control conditions (Figure 2).
Translocation of lysosomal hydrolases from the lysosomal
lumen to the rest of the cell followed by the impairment
in the lysosomal membrane function is known as lysoso-
mal membrane permeabilization (LMP) [31]. Often, these
hydrolases facilitate apoptosis by inducing mitochondrial
outer-membrane permeabilization and caspase activation
[32]. In our results, the main LMP consequence such as weak
lysosome acidification pattern and cytoplasmic acidification
was clearly evident (Figure 3). Being aweak base chloroquine,
acts as lysosomotropic drug that raises intralysosomal pH.
Hence we have monitored the release of liposomal content
by using chloroquine as a positive control. Moreover, in the
Figure 3, it is very clear that cells treated with girinimbine
resented a weak lysosome acidification pattern followed by
an increase in cytoplasmic acidification. Bearing in mind the
significance of acidic lysosome environment for proteins and
organelles degradation, it can be pointed out that; autophagy
may not the main event of cell death.
Destabilization of the lysosomal membrane may be
caused by increased production of ROS via massive peroxi-
dation of membrane lipids [33]. Moreover, many studies had
showed the relation between ROS and apoptosis induced in
cells exposed to cytotoxic drugs [34]. Mitochondrial ROS are
used as active mediators in the regulation of cell death [35].
In our study, the generation of ROS led to the upregulation of
cytoprotective protein markers HSP 60, 70, and 27. Figure 4
clearly shows that girinimbine exposure leads to increase of
ROS accumulation, but inhibition of ROSby ascorbic acid did
not prevent girinimbine-induced apoptosis, indicating that
ROS generation is not critical for the induction of apoptosis
by girinimbine in A549 cells. Moreover, the treatment with
girinimbine significantly decreases the cell number, nuclear
area, and cell membrane permeability as shown by the
multiparameter apoptosis analysis. In addition, the complex
role of mitochondria in A549 cell apoptosis was investigated.
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Figure 6: Quantitative analysis of girinimbine mediated apoptosis parameter. Changes in total nuclear intensity (a), cell permeability
(b), mitochondrial membrane potential (c), and cytochrome c localization (d) were measured simultaneously in A549 cells. Following
treatment with girinimbine, we saw statistically significant increase in total nuclear intensity, increased cell permeability, loss ofmitochondrial
membrane potential, and cytochrome c release frommitochondria. Each experiment was performed at least two times. Results are expressed
as the means ± SD. Statistical analysis was performed with one-way analysis of variance (ANOVA) using GraphPad Prism software (version
4.0; GraphPad Software Inc., San Diego, CA). Statistical significance is expressed as ∗∗𝑃 < 0.01; ∗𝑃 < 0.05.
Mitochondria have been described to play a central role in the
apoptotic process due to the mitochondrial proteins ability to
activate cellular apoptotic programs directly [36]. Detection
of changes in mitochondrial membrane potential (Ψm) was
carried out as it is assumed that its disruption is the onset
ofmitochondrial membrane transition pores (MPTP) forma-
tion. The present study revealed that girinimbine may act on
mitochondria, causing loss of Ψm and subsequent apoptosis.
This kind of Ψm reduction and generation of MPTP must
facilitate the relocalization of apoptogenic proteins from one
subcellular compartment such as mitochondria to cytoplasm
to gain access to their substrates or interacting partners [37].
The multi cytotoxicity assay shows that girinimbine ind-
uced cell death could be through the classical mitochondrial
pathway with cytochrome c release and caspase-dependent
apoptosis. The translocation of cytochrome c, a component
of themitochondrial electron transfer chain, was significantly
increased upon girinimbine treatment. In the mitochondria
mediated apoptosis, cytochrome c in turn binds to Apaf-
1 to form a complex, which triggers its oligomerization to
form the apoptosome. The caspase-9 holoenzyme is then
forms due to the binding of procaspase-9 to the apop-
tosome and sequentially cleaves and activates the down-
stream caspases, such as caspase-3 [38]. Our findings on
the upregulation of caspase 3/7, caspase 9, reduction in Ψm,
and release of cytochrome c to the cytosol substantiate this
theory and strongly support the involvement ofmitochondria
in the apoptosis induced by girinimbine in A549 cells.
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Figure 7: Cells were lysed and protein arrays were performed. Cells was treated with 19𝜇M girinimbine for 24 h and the whole cell protein
was extracted. Equal amount of (300 𝜇g) of protein from each sample was used for the assay. Quantitative analysis in the arrays showed
differences in the apoptotic markers (a). Representative images of the apoptotic protein array are shown for the control (b), treatment (c), and
the exact protein name of each dot in the array (d).
Suppression of apoptosis may promote the cancer develop-
ment by inhibiting the chemotherapy as well as other forms of
inducers of cell death [39]. Regulation of apoptosis has been
censoriously dependent on several genes, which have been
identified earlier and includes XIAP-a member of the IAP
family. It has the capacity to inhibit the activation of caspases
3, 7, and 9 [40]. In our study, we found that girinimbine
treatment of A549 cells caused inhibition of XIAP, but SMAC,
an antagonist to XIAP, could be found to be slightly regulated
in this treatment concentration. This is considered as a key
event in the execution of cell death, which is regulatedmainly
by proteins of the Bcl-2 family [41, 42].
Critical issues in apoptosis include the dominance of
anti-versus proapoptotic Bcl-2 members [43]. Girinimbine is
found to induce apoptosis in the A549 cells, involving
downregulated Bcl-2 expression. This downregulation was
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Figure 8: Effect of girinimbine on activation of caspases 3/7, 8, and 9.
Cells were treated with girinimbine at the indicated concentrations
for 24 h and activity was determined by using a luminescent
enzyme assay kit. Each point represents the mean ± SD of three
different experiments. Statistical analysis was performed with one-
way analysis of variance (ANOVA) using GraphPad Prism software
(version 4.0; GraphPad Software Inc., San Diego, CA). Statistical
significance is expressed as ∗∗𝑃 < 0.01; ∗𝑃 < 0.05.
concomitant with the upregulation of Bad, Bax, and Bim,
which inhibits antiapoptotic proteins and render the cells
more susceptible to apoptogenic stimuli (Figure 7). The
release of cytochrome c found in our study could be due to
the up regulated Bax, since Bax in association with adenine
nucleotide translocator within the permeability transition
pore complex will increase the mitochondrial membrane
permeability, and thereby discharge a number of apopto-
genic molecules into the cytosol [44]. In addition to this,
upregulation of the tumor suppressor protein p53, which has
a critical role in regulation of the Bcl-2, and p27, and p21,
draws attention to the involvement of cell cycle arrest in the
apoptosis process. Alternatively we found the involvement of
extrinsic pathway proteins such as Fas and FasL upregulation,
and related upregulation of caspase 8 (Figure 7). Moreover,
the luminescent based caspase 8 assay had showed 10 fold
differences than the control. Apart from this, we found
that there is a downregulation of Bid happening too. Since
mitochondrial damage in the Fas pathway of apoptosis is
mediated by the caspase 8 cleavage of Bid, [45] the findings
here shows the cross talk between intrinsic and extrinsic
pathways.
The protein array results exhibited a significant reduction
of both IGF-I and IGF-II. IGF-I has been shown to exert
strongmitogenic and antiapoptotic effects in a variety of nor-
mal and cancerous cells, including lung cancer cell lines [46].
Moreover the over expression of IGFBP3 is closely associated
with the downregulation of IGF-I and its mitogenic activity
[47]. It is known that IGFBP-2 and IGFBP-1 are involved in
the regulation of cell migration, apoptosis, and cell growth
[48]. Both are reported to be markedly overexpressed in
many tumors and tumor cell lines. And it is assumed that
elevation of the IGFBP-2 production is part of a mechanism
to compensate for the mitogenic and antiapoptotic effects
of tumor-derived IGFs [49]. Our data clearly showed the
downregulation of IGFBP1 and IGFBP2 concomitant with
upregulation of IGBP3.
Our results provided a new insight into the mechanism
of chemotherapeutic properties of Murraya koenigii. In
addition, these study findings demonstrate that girinimbine
mediates its apoptotic effects through both intrinsic and
extrinsic pathway, which is depended on caspase mediation.
Moreover, the upregulation of p53 as well as the cell prolifer-
ation repressor proteins, p27 and p21, and the significant role
of insulin/IGF-1 signaling were also identified. These results
indicate that girinimbine could be a candidate for a novel
anticancer agent.Therefore,more in-depth in vitro and in vivo
studies are currently going on in our laboratory.
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